Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study

Bengt Klarin, Göran Molin, Bengt Jeppsson, Anders Larsson, Bengt Klarin, Göran Molin, Bengt Jeppsson, Anders Larsson

Abstract

Introduction: Ventilator-associated pneumonia (VAP) is usually caused by aspiration of pathogenic bacteria from the oropharynx. Oral decontamination with antiseptics, such as chlorhexidine (CHX) or antibiotics, has been used as prophylaxis against this complication. We hypothesised that the probiotic bacteria Lactobacillus plantarum 299 (Lp299) would be as efficient as CHX in reducing the pathogenic bacterial load in the oropharynx of tracheally intubated, mechanically ventilated, critically ill patients.

Methods: Fifty critically ill patients on mechanical ventilation were randomised to either oral mechanical cleansing followed by washing with 0.1% CHX solution or to the same cleansing procedure followed by oral application of an emulsion of Lp299. Samples for microbiological analyses were taken from the oropharynx and trachea at inclusion and at defined intervals thereafter.

Results: Potentially pathogenic bacteria that were not present at inclusion were identified in oropharyngeal samples from eight of the patients treated with Lp299 and 13 of those treated with CHX (p = 0.13). Analysis of tracheal samples yielded similar results. Lp299 was recovered from the oropharynx of all patients in the Lp299 group.

Conclusions: In this pilot study, we found no difference between the effect of Lp299 and CHX used in oral care procedures, when we examined the effects of those agents on colonisation of potentially pathogenic bacteria in the oropharynx of intubated, mechanically ventilated patients.

Figures

Figure 1
Figure 1
Results of oropharyngeal cultures. Number of patients with and without emerging enteric bacteria, not identified at inclusion. No new enteric species (ie, taxa not found at inclusion) appeared in 65% (15 of 23) of the patients in the Lp299 group compared with 38% (8 of 21) in the control group.
Figure 2
Figure 2
Distribution of the findings of emerging enteric bacteria. On the first days of ICU care, identified emerging enteric species were twice as many in the control patients. Despite a gradual decrease in the number of patients remaining in the study (similar in both groups), new cases of tracheal infection appeared in the latter part of the study period, primarily in the control group.

References

    1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903.
    1. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med. 2005;33:2184–2193. doi: 10.1097/01.CCM.0000181731.53912.D9.
    1. Rello J, Kollef M, Diaz E, Sandiumenge A, del Castillo Y, Corbella X, Zachskorn R. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med. 2006;34:2766–2772. doi: 10.1097/01.CCM.0000242154.49632.B0.
    1. Bergmans DCJJ, Bonten MJM, Gaillard CA, Paling JC, Geest S van der, van Tiel FH, Beysens AJ, de Leeuw PW, Stobberingh EE. Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2001;164:382–388.
    1. Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger L, Gleich P, Ruckdeschel G. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination. Intensive Care Med. 1996;23:187–195. doi: 10.1007/s001340050314.
    1. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia: A randomized, placebo-controlled, double-blind clinical trial. JAMA. 1991;265:2704–2710. doi: 10.1001/jama.265.20.2704.
    1. D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: Systematic review of randomised controlled trials. BMJ. 1998;316:1275–1285.
    1. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical patients: A systematic review of the evidence. Arch Surg. 1999;134:170–176. doi: 10.1001/archsurg.134.2.170.
    1. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: A randomized controlled trial. Lancet. 2003;362:1011–1016. doi: 10.1016/S0140-6736(03)14409-1.
    1. Kollef MH. Selective digestive decontamination should not be routinely employed. Chest. 2003;123:464s–468s. doi: 10.1378/chest.123.5_suppl.464S.
    1. Chlebick MP, Safdar N. Topical chlorhexidine for prevention of ventilator-associated pneumonia: A meta-analysis. Crit Care Med. 2007;35:595–602. doi: 10.1097/.
    1. Chan EY, Ruest A, O Meade M, Cook DJ. Oral decontamination for prevention of systematic review and meta-analysis pneumonia in mechanically ventilated adults. BMJ. 2007;334:889. doi: 10.1136/.
    1. Free RH, Mei HC Van der, Dijk F, Van Weissenbruch R, Busscher HJ, Albers FWJ. Biofilm formation on voice prostheses: In vitro influence of probiotics. Ann Otol Rhinol Laryngol. 2001;110:946–951.
    1. Schwandt LQ, van Weissenbruch R, Mei HC van der, Busscher HJ, Albers FWJ. Effect of dairy products on the lifetime of Provox2 voice prostheses in vitro and in vivo. Head Neck. 2005;27:471–477. doi: 10.1002/hed.20180.
    1. Johansson M-L, Molin G, Jeppsson B, Nobaek S, Ahrné S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol. 1993;59:15–20.
    1. Klarin B, Johansson M-L, Molin G, Larsson A, Jeppsson B. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Critical Care. 2005;9:R285–R293. doi: 10.1186/cc3522.
    1. Stjernquist-Desatnik A, Warfving H, Johansson M-L. Persistence of Lactobacillus plantarum DSM 9843 on human tonsillar surface after oral administration in fermented oatmeal gruel. A pilot study. Acta Otolaryngol. 2000;543:215–219. doi: 10.1080/000164800454422.
    1. Johansson M-L, Quednau M, Molin G, Ahrné S. Randomly Amplified Polymorphic DNA (RAPD) for rapid typing of Lactobacillus plantarum strains. Lett Appl Microbiol. 1995;21:155–159. doi: 10.1111/j.1472-765X.1995.tb01030.x.
    1. Murray JR, Matthay MA, Luce JM, Flick R. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720–723.
    1. Klompas M. Does This Patient Have Ventilator-Associated Pneumonia? JAMA. 2007;297:1583–1593. doi: 10.1001/jama.297.14.1583.
    1. Cankaya H, Ozen S, Kiroğlu F, Yurttaş V. Effects of topical chlorhexidine applied to the rabbit nasal mucosa. Auris Nasus Larynx. 2003;30:65–69. doi: 10.1016/S0385-8146(02)00102-5.
    1. Tantipong H, Morkchareonpong C, Jaiyindee S, Thamlikitkul V. Randomized Controlled Trial and Meta-analysis of Oral Decontamination with 2% Chlorhexidine Solution for the Prevention of Ventilator-Associated Pneumonia. Infect Control Hosp Epidemiol. 2008;29:131–136. doi: 10.1086/526438.
    1. Spijkervet FKL, van Saene HKF, Panders AK, Vermey A, van Saene JJM, Mehta DM, Fidler V. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol. 1989;67:154–161. doi: 10.1016/0030-4220(89)90321-6.
    1. Spijkervet FK, van Saene JJ, van Saene HK, Panders AK, Vermey A, Fidler V. Chlorhexidine inactivation by saliva. Oral Surg Oral Med Oral Pathol. 1990;69:444–449. doi: 10.1016/0030-4220(90)90377-5.
    1. Vali L, Davies SE, Lai LLG, Dave J, Amyes SGB. Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates. J Antimicrob Chemother. 2008;61:524–532. doi: 10.1093/jac/dkm520.
    1. Salvana EMT, Frank M. Lactobacillus endocarditis: Case report and review of cases reported since 1992. J Infect. 2006;53:e5–e10. doi: 10.1016/j.jinf.2005.10.005.
    1. Salminen MK, Rautelin H, Tynkkynen S, Poussa , Saxelin M, Valtonen V. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62–69. doi: 10.1086/380455.
    1. Cannon JP, Lee TA, Bolanos JT, Danziger Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005;24:31–40. doi: 10.1007/s10096-004-1253-y.
    1. Adawi D, Molin G, Ahrne S, Jeppsson B. Safety of the Probiotic Strain Lactobacillus plantarum DSM 9843 (= strain 299v) in an Endocarditis Animal Model. Microbial Ecol Health Disease. 2002;14:50–53. doi: 10.1080/089106002760002766.
    1. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74:123–128. doi: 10.1097/00007890-200207150-00021.
    1. Oláh A, Belágyi T, Issekutz Á, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg. 2002;89:1103–1107. doi: 10.1046/j.1365-2168.2002.02189.x.
    1. McNaught CE, Woodcock NP, MacFie J, Mitchell CJ. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut. 2002;51:827–831. doi: 10.1136/gut.51.6.827.
    1. McNaught CE, Woodcock NP, Anderson ADG, MacFie J. A prospective randomised trial of probiotics in critically ill patients. Clin Nutr. 2005;24:211–219. doi: 10.1016/j.clnu.2004.08.008.
    1. Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008;52:1096–1102.
    1. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, Harst E van der, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG, for the Dutch Acute Pancreatitis Study Group Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–659. doi: 10.1016/S0140-6736(08)60207-X.
    1. Koeman M, Ven AJAM van der, Hak E, Joore HCA, Kaasjager K, de Smet AGA, Ramsay G, Dormans TPJ, Aarts LPHJ, de Bel EE, Hustinx WNM, Tweel I van der, Hoepelman AM, Bonten MJM. Oral Decontamination with Chlorhexidine Reduces the Incidence of Ventilator-associated Pneumonia. Am J Respir Crit Care Med. 2006;173:1348–1355. doi: 10.1164/rccm.200505-820OC.
    1. Crossner CG, Claesson R, Johansson T. Presence of mutans streptococci and various types of lactobacilli in interdental spaces related to development of proximal carious lesions. Scand J Dent Res. 1989;97:307–315.
    1. Näse L, Hatakka K, Savilahti E, Saxelin M, Pönkä A, Poussa T. Effect of long-term consumption of a probiotic bacterium Lactobacillus rhamnosus GG in milk on dental caries and caries risk in children. Caries Res. 2001;35:412–420. doi: 10.1159/000047484.
    1. Ahola AJ, Yli-Knuuttila H, Suomalainen T, Poussa T, Ahlström A, Meurman JH, Korpela R. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch Oral Biol. 2002;47:799–804. doi: 10.1016/S0003-9969(02)00112-7.
    1. Köll-Klais P, Mändar R, Leibur E, Marcotte H, Hammarström L, Mikelsaar M. Oral lactobacilli in chronic periodontitis and periodontal health: species composition and antimicrobial activity. Oral Microbiol Immunol. 2005;20:354–361. doi: 10.1111/j.1399-302X.2005.00239.x.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel